MitraClip™ implantation plus left atrial appendage occlusion in a hereditary hemorrhagic telangiectasia patient

Future Cardiol. 2022 Nov;18(11):849-855. doi: 10.2217/fca-2022-0043. Epub 2022 Sep 21.

Abstract

Hereditary hemorrhagic telangiectasia is regarded as a high hemorrhagic risk condition, and the management of anticoagulation and heart surgery in these patients can be challenging. The authors describe a combined percutaneous treatment of mitral regurgitation and left atrial appendage occlusion in a patient affected by hereditary hemorrhagic telangiectasia and atrial fibrillation, supporting the safety and feasibility of the procedure and the optimal short-term outcome.

Keywords: MitraClip; atrial fibrillation; hemostasis; hereditary hemorrhagic telangiectasia; interventional; left atrial appendage occlusion; mitral regurgitation.

Plain language summary

Hereditary hemorrhagic telangiectasia is a disease that carries a high risk of bleeding because of the growth of blood vessels with weak walls. The authors describe the case of a patient with hereditary hemorrhagic telangiectasia needing an intervention for mitral valve regurgitation and anticoagulation therapy for atrial fibrillation. To reduce the bleeding risk, two innovative techniques were used: the mitral valve disease was treated with the percutaneous implantation of stitches without open chest surgery and the left atrial appendage was contextually occluded thanks to another mini-invasive procedure to avoid the need for anticoagulation.

MeSH terms

  • Atrial Appendage* / diagnostic imaging
  • Atrial Appendage* / surgery
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / surgery
  • Cardiac Surgical Procedures* / methods
  • Humans
  • Mitral Valve Insufficiency* / diagnosis
  • Mitral Valve Insufficiency* / etiology
  • Mitral Valve Insufficiency* / surgery
  • Stroke*
  • Telangiectasia, Hereditary Hemorrhagic* / complications
  • Treatment Outcome